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ORIGINAL RESEARCH

Determinants and Outcomes of Vasoplegia Following Left Ventricular
Assist Device Implantation
Kristen M. Tecson, PhD; Brian Lima, MD; Andy Y. Lee, MD; Fayez S. Raza, MD; Grace Ching, BS; Cheng-Han Lee, BS; Joost Felius, PhD;
Ronald D. Baxter, MD; Sasha Still, MD; Justin D. G. Collier, MD; Shelley A. Hall, MD; Susan M. Joseph, MD

Background-—Vasoplegia is associated with adverse outcomes following cardiac surgery; however, its impact following left
ventricular assist device implantation is largely unexplored.
Methods and Results-—In 252 consecutive patients receiving a left ventricular assist device, vasoplegia was deﬁned as the
occurrence of normal cardiac function and index but with the need for intravenous vasopressors within 48 hours following surgery
for >24 hours to maintain a mean arterial pressure >70 mm Hg. We further categorized vasoplegia as none; mild, requiring 1
vasopressor (vasopressin, norepinephrine, or high-dose epinephrine [>5 lg/min]); or moderate to severe, requiring ≥2
vasopressors. Predictors of vasoplegia severity were determined using a cumulative logit (ordinal logistic regression) model,
and 1-year mortality was evaluated using competing-risks survival analysis. In total, 67 (26.6%) patients developed mild vasoplegia
and 57 (22.6%) developed moderate to severe vasoplegia. The multivariable model for vasoplegia severity utilized preoperative
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) proﬁle, central venous pressure, systolic blood
pressure, and intraoperative cardiopulmonary bypass time, which yielded an area under the curve of 0.76. Although no signiﬁcant
differences were noted in stroke or pump thrombosis rates (P=0.87 and P=0.66, respectively), respiratory failure and major
bleeding increased with vasoplegia severity (P<0.01). Those with moderate to severe vasoplegia had a signiﬁcantly higher risk of
mortality than those without vasoplegia (adjusted hazard ratio: 2.12; 95% conﬁdence interval, 1.08–4.18; P=0.03).
Conclusions-—Vasoplegia is predictive of unfavorable outcomes, including mortality. Risk factors for future research include
preoperative INTERMACS proﬁle, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass
time. ( J Am Heart Assoc. 2018;7:e008377. DOI: 10.1161/JAHA.117.008377.)
Key Words: left ventricular assist device • vasoplegia

V

asoplegia is a complication of surgery characterized by
excessive vasodilation and low systemic vascular resistance that develops in 5% to 25% of patients undergoing
cardiopulmonary bypass (CPB).1,2 Although a number of
studies have assessed vasoplegia in heart transplantation,
data are sparse for advanced heart failure (HF) patients who
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receive a left ventricular assist device (LVAD). Preliminary
studies have shown that HF patients are at risk of developing
vasoplegia after LVAD surgery, but nothing has been reported,
to our knowledge, to classify vasoplegia according to severity
in LVAD recipients or to assess its effect on surgical
outcomes. For these reasons, we sought to identify modiﬁable
risk factors and to describe the consequences of vasoplegia
following LVAD implantation.

Methods
Clinical
We compiled data on consecutive patients undergoing LVAD
implantation surgery from June 2008 to May 2016 at the
Baylor University Medical Center, after receiving approval
from Baylor Scott and White Research Institute’s institutional
review board (with a waived requirement of informed
consent). We followed the framework of Chan and colleagues
by deﬁning vasoplegia as the occurrence of normal cardiac
function and index but with the need for intravenous
vasopressors within 48 hours following surgery for >24 hours
Journal of the American Heart Association
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What Is New?
• In this ﬁrst study to assess the severity of vasoplegia
following left ventricular assist device implantation, we
demonstrated that vasoplegia was a common complication,
with 27% of patients developing a mild form and 23%
developing a moderate to severe form, and that functional
status, preoperative central venous pressure, preoperative
systolic blood pressure, and cardiopulmonary bypass time
were predictive of vasoplegia development and severity.

What Are the Clinical Implications?
• Because vasoplegia was associated with worse survival
outcomes, future work is warranted to help inform physicians about how to prevent and/or mitigate vasoplegia.

to maintain a mean arterial pressure >70 mm Hg.3 As in
Esmailian and colleagues’ work, we further categorized
vasoplegia as none; mild, requiring 1 vasopressor (vasopressin, norepinephrine, or high-dose epinephrine [>5 lg/
min]); or moderate to severe, requiring ≥2 vasopressors.4 The
list of pre- and intraoperative variables examined are in
Table 1. Postoperative outcomes were primarily evaluated
using the Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) deﬁnitions. A major bleed,
for example, was deﬁned as suspected internal or external
bleeding resulting in death, reoperation, hospitalization, or
transfusion of red blood cells (≥4 U packed red blood cells
within any 24-hour period during ﬁrst 7 days after implantation). Furthermore, right HF (RHF) was deﬁned as signs and
symptoms of persistent right ventricular dysfunction following
LVAD implantation and was categorized based on the duration
of inotropes: mild, ≤7 days; moderate, 8–14 days; severe,
>14 days; or severe acute, requiring a right ventricular assist
device. Patients were followed for up to 1 year after
transplant. The primary outcomes following transplantation
were survival at 30 days and 1 year. The data, analytic
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure.

Statistical Analysis
We used the Wilcoxon rank sum test to examine differences in
patient and surgical characteristics across vasoplegia severity
for skewed continuous variables, and ANOVA was used for
normally distributed variables. We used the Cochran–
Armitage test for trend and the Kruskal–Wallis test to do
the same for categorical variables. We also used the Cochran–
Armitage test for trend to examine differences in postsurgical
outcomes. Preoperative and intraoperative variables having
DOI: 10.1161/JAHA.117.008377

signiﬁcant relations with vasoplegia severity in bivariate
analyses (ie, those with P<0.05 in Table 1) were considered
jointly in a multivariable cumulative logit (ordinal logistic
regression) model constructed via stepwise selection, using a
signiﬁcance level of 0.10 to stay in the model. Finally, we
utilized the Fine and Gray method to assess the effect of
vasoplegia severity on the outcome of survival while accounting for the competing risk of transplantation; we repeated the
analysis after adjusting for age and INTERMACS proﬁle.5 For
simplicity, we refer to survival and mortality in this article, yet
we truly mean transplant-free survival and transplant-free
mortality, as we performed a competing-risks analysis.
Continuous variables are reported as median (quartile 1,
quartile 3). Categorical variables are reported as frequencies
and percentages. Analyses were performed using SAS version
9.4 (SAS Institute).

Results
This analysis included 252 patients, of which 128 (50.8%) did
not develop vasoplegia, 67 (26.6%) developed mild vasoplegia,
and 57 (22.6%) developed moderate to severe vasoplegia
following LVAD implantation. Overall, 203 (80.6%) patients
were male, the median age was 59 (49, 66) years, and 92%
(232) of devices implanted were HeartMate II (Thoratec). Eight
patients (3.2%) used extracorporeal membrane oxygenation
before LVAD placement; its use was not associated with
vasoplegia severity (P=0.15). Generally, demographic information, comorbidities, and medication use were similar
across vasoplegia severity categories (Table 1).
Among preoperative variables, we found that length of stay
(LOS), serum creatinine, and central venous pressure (CVP)
increased as the severity of vasoplegia worsened (P=0.03,
0.03, <0.01, respectively) (Table 1). The INTERMACS proﬁle,
MELD (Model for End-Stage Liver Disease), and HeartMate II
risk score all revealed a similar pattern; the worse the
preoperative risk scores, the greater the vasoplegia severity.
Those who required vasopressors before surgery were 3.2
times (95% conﬁdence interval [CI], 1.6–6.6) more likely to
develop a mild or worse form of vasoplegia following LVAD
implantation (P<0.01). Higher values for preoperative systolic
blood pressure (SBP), diastolic blood pressure, mean arterial
pressure, and systemic vascular resistance exhibited protective effects against vasoplegia (P<0.01, P=0.04, P<0.01, and
P=0.05, respectively). Those without vasoplegia, for example,
had a median SBP of 109 mm Hg compared with a median of
99 mm Hg for those who had moderate to severe vasoplegia.
Among intraoperative variables examined, CPB time, crossclamp use, and volume removed by ultraﬁltration were all
signiﬁcantly higher as vasoplegia severity worsened (P<0.01,
P<0.01, and P=0.03, respectively). Those who did not develop
vasoplegia, for example, had a median CPB duration of
Journal of the American Heart Association
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Table 1. Preoperative and Intraoperative Sample Characteristics By Vasoplegia Severity
Variable

None (n=128)

Mild (n=67)

Moderate/Severe (n=57)

P Value

104 (81.3)

51 (76.1)

48 (84.2)

0.81

Preoperative
Sex, male
Age, y

60 (49.5, 67.5)

58 (48, 67)

57 (49, 64)

0.47

Body mass index, kg/m2

28.7 (25, 33.9)

30.4 (23.9, 34.1)

30.6 (25.3, 35.6)

0.77

Diabetes mellitus

55 (43.0)

26 (38.8)

22 (38.6)

0.53

COPD

17 (13.3)

4 (6.0)

4 (7.0)

0.12

Destination therapy10

56 (44.8)

34 (52.3)

29 (55.8)

0.15

Prior sternotomy

46 (35.9)

21 (31.3)

18 (31.6)

0.50

13 (10.2)

6 (9.0)

9 (15.8)

Ischemic cardiomyopathy

1

0.35
<0.01

INTERMACS
1

12 (9.4)

17 (25.4)

14 (24.6)

2

43 (33.6)

19 (28.4)

28 (49.1)

3

52 (40.6)

27 (40.3)

13 (22.8)

4

21 (16.4)

4 (6.0)

2 (3.5)

12 (10, 15)

14 (11, 16)

15 (12, 19)

<0.01

1.7 (2.2, 1.2)

1.9 (1.4, 2.2)

2.1 (1.6, 2.6)

0.02

ACE inhibitor

71 (55.5)

39 (58.2)

30 (52.6)

0.81

Aldosterone

80 (62.5)

41 (61.2)

35 (61.4)

0.87

MELD score

1

HeartMate II risk score1
Medication (in past year)

1

42 (33.1)

29 (43.3)

26 (45.6)

0.08

ARB1

15 (11.8)

4 (6.0)

11 (19.3)

0.29

Antiplatelet

86 (67.2)

39 (58.2)

42 (73.7)

0.62

b-blocker

112 (87.5)

56 (83.6)

48 (84.2)

0.48

Warfarin1

53 (41.7)

21 (31.3)

18 (31.6)

0.13

Vasopressor-dependent

12 (9.4)

17 (25.4)

14 (24.6)

<0.01
0.01

Amiodarone

Heart rate, beats/min

84 (73.5, 95)

83 (77, 93)

95 (81, 107)

SBP, mm Hg2

109 (98, 121)

98 (90, 110)

99 (88.5, 111.5)

<0.01

DBP,* mm Hg2

70 (62, 77)

64 (56, 73)

64.5 (60, 73)

0.04

MAP, mm Hg2

82 (75, 91)

74 (69, 85)

77 (70.5, 85)

<0.01

Systemic vascular resistance, PRU10

1288 (1021, 1643)

1261 (888, 1670)

1128 (909, 1450)

0.05

Serum creatinine, mg/dL

1.4 (1.1, 1.7)

1.4 (1.1, 1.9)

1.6 (1.3, 1.8)

0.03

LOS, d

4 (1, 9.5)

6 (2, 12)

7 (3, 13)

0.03

CVP, mm Hg1

13 (8, 17)

16 (12, 21)

18 (12, 22)

<0.01

HeartMate II

117 (91.4)

60 (89.6)

55 (96.5)

HeartMate III

3 (2.3)

2 (3.0)

1 (1.8)

HeartWare

8 (6.3)

5 (7.5)

1 (1.8)

31 (24.2)

24 (35.8)

22 (38.5)

0.03

Intraoperative
Device type

0.67

Concomitant procedure
CPB time, min

69 (53, 85)

90.5 (72, 126)

92 (70, 119)

<0.01

Cross-clamp use3

4 (3.1)

8 (11.9)

8 (14.0)

<0.01

Volume ultrafiltrated, mL15

1500 (0, 2725)

2000 (1200, 3900)

2000 (0, 3500)

0.03

27 (24, 30)

26 (23, 30)

26 (24, 30)

0.89

11

2

Nadir hematocrit, %

Data are shown as frequency (%) or median (quartile 1, quartile 3). Superscripts indicate the number of missing values. Variables with P<0.05 were considered in a multivariable model
(with the exception of MELD and HeartMate risk scores). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease;
CPB, cardiopulmonary bypass; CVP, central venous pressure; DBP, diastolic blood pressure; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LOS, length of
stay; MAP, mean arterial pressure; MELD, Model for End-Stage Liver Disease; PRU, peripheral resistance unit; SBP, systolic blood pressure.
*Diastolic blood pressure was normally distributed; the P value is from ANOVA.

DOI: 10.1161/JAHA.117.008377
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Table 2. Maximum Likelihood Estimates for the Ordinal
Logistic Regression Model for Vasoplegia Severity
Parameter

Vasoplegia

Estimate

SE

P Value

Intercept

Moderate/severe

0.137

1.022

0.89

Intercept

Mild

CVP

Moderate/severe

0.024

0.713

1.011

0.48

0.023

0.29

CVP

Mild

0.055

0.021

<0.01

CPB time

Moderate/severe

0.008

0.004

0.02

CPB time

Mild

0.026

0.005

<0.01

INTERMACS (1)

Any severity

0.606

0.273

0.03

INTERMACS (2)

Any severity

0.297

0.229

0.20

INTERMACS (3)

Any severity

0.123

0.228

0.59

Systolic blood
pressure

Any severity

0.023

0.008

<0.01

Vasoplegia group none is the reference for intercept, CVP, and CPB time. CPB indicates
cardiopulmonary bypass; CVP, central venous pressure; INTERMACS, Interagency
Registry for Mechanically Assisted Circulatory Support.

DOI: 10.1161/JAHA.117.008377

decreased as vasoplegia worsened (none: 11.7%; mild, 4.5%;
moderate to severe, 0.0%; P<0.01).
Within 30 days of LVAD implantation, only 1 patient
(0.79%) without vasoplegia died, 6 (9.0%) with mild vasoplegia
died, and 10 (17.5%) with moderate to severe vasoplegia died.
The survival rates and curves differed signiﬁcantly across the
vasoplegia categories at 30 days (P<0.01). One-year mortality
rates increased across severity (23.3%, 29.6%, and 36.0%);
however, the trend did not reach statistical signiﬁcance
(P=0.10). When considered as a time-to-event outcome, those
with moderate to severe vasoplegia had a signiﬁcantly higher
risk of mortality than those without vasoplegia (adjusted
hazard ratio: 2.12; 95% CI, 1.08–4.18; P=0.03). Alternatively,
the risk of mortality for those with mild vasoplegia did not
differ from those without vasoplegia (adjusted hazard ratio:
1.28; 95% CI, 0.67–2.45; P=0.45; Figure 2, Table 4).

Discussion
Approximately half of the 252 patients in this analysis
developed vasoplegia following LVAD implantation. We found
that the best combination of variables to predict the severity
of vasoplegia was preoperative INTERMACS proﬁle, CVP, SBP,
and intraoperative CPB duration. In addition, bivariate analyses revealed that preoperative serum creatinine and LOS as
well as intraoperative cross-clamp use and volume removed
via ultraﬁltration were associated with the development of
vasoplegia. The severity of vasoplegia was associated with
longer postoperative LOS, major bleeding, and mortality. In
comparison to patients without vasoplegia, those with
moderate to severe vasoplegia had more than double the
risk of 1-year mortality.
Rates of vasoplegia vary and depend heavily on the type of
surgery and the clinical characteristics of the patient sample
as well as the deﬁnition of vasoplegia. For example, vasoplegia deﬁned as norepinephrine ≥0.2 lg/kg per minute for 12
to 24 hours in the intensive care unit was observed in 20% of
HF patients undergoing elective cardiac surgery compared
with 0% of similarly matched patients without HF undergoing
the same surgery.6 A recent retrospective analysis reported a
vasoplegia occurrence of 29%; however, only a small portion
of that sample was comprised patients undergoing surgery for
LVAD implantation (most had left ventricle restoration or
CorCap [Acorn Cardiovascular] implantation).7 Furthermore,
that study deﬁned vasoplegia as the need for norepinephrine ≥0.2 lg/kg per minute and/or any dose of
terlipressin combined with a cardiac index ≥2.2 L/min per
m2 for at least 12 consecutive hours within the ﬁrst 3
postoperative days. In another study, 48% and 34% of
patients undergoing CPB developed vasoplegia immediately
and 24 hours following surgery, respectively, based on mean
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69 minutes, and those who developed moderate to severe
vasoplegia had a median CPB duration of 92 minutes. No
difference was observed in intraoperative nadir hematocrit.
The multivariable model for vasoplegia severity utilized 4
variables: preoperative INTERMACS proﬁle, CVP, SBP, and
intraoperative CPB duration. This combination exhibited fair to
good predictive ability with an area under the curve of 0.76.
The model is fully described in Table 2, and the corresponding
odds ratios are in Figure 1; note that this model utilized
partial proportional odds. A patient with an INTERMACS
proﬁle of 2 is 2.94 times (95% CI, 1.02–8.50) more likely to
develop a form of vasoplegia more severe than a patient with
an INTERMACS proﬁle of 4. In addition, for every 5 minutes of
CPB, patients were 1.14 times (95% CI, 1.09–1.20) more likely
to develop a mild or worse form of vasoplegia. Furthermore,
an increase of 5 mm Hg of CVP increases the risk of
developing worse severity of vasoplegia by 32% (odds ratio:
1.32; 95% CI, 1.07–1.62). In contrast, a 5-mm Hg increase in
SBP yields a 3% to 18% protective effect against any severity
of vasoplegia (odds ratio: 0.89; 95% CI, 0.82–0.97).
Although no signiﬁcant trend was noted in stroke rate or
pump thrombosis, major bleeding events increased with
vasoplegia severity (no vasoplegia: 7.8%; mild: 17.9%; moderate to severe: 31.6%; P<0.01; Table 3). Similarly, the rates
of respiratory failure (ie, requiring mechanical ventilation
following initial extubation) and LOS increased with vasoplegia
severity. Furthermore, RHF also worsened with increased
vasoplegia severity. None of the patients without vasoplegia
had severe acute RHF compared with 11.9% of those with
mild and 14.6% of those with moderate to severe vasoplegia
(P<0.01). Alternatively, the rates of driveline infection

Vasoplegia After LVAD
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Figure 1. Odds ratios for the predictive classiﬁcation model of vasoplegia severity. CPB indicates
cardiopulmonary bypass; CVP, central venous pressure; INTERMACS, Interagency Registry for Mechanically
Assisted Circulatory Support; M:N, odds ratio for the outcome of mild vasoplegia to no vasoplegia; MS:N,
odds ratio for the outcome of moderate/severe vasoplegia to no vasoplegia; SBP, systolic blood pressure.

arterial pressure <50 mm Hg and the need for noradrenaline
perfusion >0.08 lg/kg per minute.8 Another study reported a
rate of 31% among heart transplant patients, with vasoplegia
deﬁned as “global systemic hypotension within 48 hours of
heart transplantation with concurrent requirement of vasopressor administration (eg, vasopressin, epinephrine, or
norepinephrine infusion of >5 lg/min) for >24 hours to
maintain MAP [mean arterial pressure] >70 mm Hg.”3 Similarly, in the Esmailian heart transplant study, 34% developed
vasoplegia (with the majority categorized as mild).4 We
adopted Chan and colleagues’ deﬁnition of vasoplegia and
observed a rate of 49%, which was the highest of the studies
reviewed and may be explained by the greater severity of
illness in LVAD patients compared with heart transplantation
patients.
The use of CPB in cardiac surgery has been frequently
linked with vasoplegia, with the rate of vasoplegia being
higher for patients who have CPB than for those who have offpump coronary artery bypass surgery.9 Our study also
reﬂected this inﬂammatory cascade, with worsening vasoplegia as CPB duration increased. The rates of concomitant
procedures also increased across the vasoplegia severities,
which may partly explain the increased CPB durations. In
DOI: 10.1161/JAHA.117.008377

addition, both valvular surgery and surgery for the treatment
of HF have been associated with the development of
vasoplegia.10 Consequently, all participants in our study
(having advanced HF and LVAD) were already susceptible to
developing vasoplegia. Having a prior sternotomy has also
been associated with the development of vasoplegia among
heart transplant patients; however, this relation was not
detected in our LVAD recipient cohort.4 Vasoplegia development has been directly associated with angiotensin-converting enzyme inhibitors and heparin,11 whereas the use of bblockers exhibits an indirect relation (ie, a protective effect).7
We did not conﬁrm the associations between those drugs and
vasoplegia; however, patients in the previous studies were
treated with angiotensin-converting enzyme inhibitors and bblockers at much different rates than in our study. The use of
amiodarone did trend toward signiﬁcance in our study
(P=0.08) and has been previously associated with vasoplegia
in the heart transplantation population.12 In addition, the use
of vasopressors before LVAD implantation has been associated with poor outcomes and RHF; we found that those with
vasopressor dependence before surgery had >3 times the risk
of developing vasoplegia.13 Our study revealed preoperative
kidney dysfunction as being associated with vasoplegia, with
Journal of the American Heart Association
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Table 3. Postoperative Sample Characteristics by Vasoplegia Severity

Variable

None (n=128)

Mild (n=67)

Moderate/Severe
(n=57)

P Value

Major bleed

10 (7.8)

12 (17.9)

18 (31.6)

<0.01
<0.01

RHF*
None or mild

113 (91.1)

46 (68.7)

35 (63.6)

Moderate

5 (4.0)

7 (10.5)

10 (18.2)

Severe

6 (4.8)

6 (9.0)

2 (3.6)

Severe acute

0 (0.0)

8 (11.9)

8 (14.6)

Gastrointestinal bleed

17 (13.3)

6 (9.0)

5 (8.8)

0.31

Pump thrombosis

17 (13.3)

5 (7.5)

7 (12.3)

0.66

Driveline infection

15 (11.7)

3 (4.5)

0 (0.0)

<0.01

Respiratory failure

19 (14.8)

15 (22.4)

28 (49.1)

<0.01

Stroke

18 (14.1)

7 (10.5)

8 (14.0)

0.87

13.0 (10.0, 17.5)

16.0 (13.0, 24.0)

16.0 (14.0, 24.0)

<0.01

1 (0.79)

6 (9.0)

10 (17.5)

<0.01

24 (23.3)

16 (29.6)

18 (36.0)

0.10

Postoperative LOS (d)
30-d mortality

†

1-y mortality†

Data are shown as frequency (%) or median (quartile 1, quartile 3). LOS indicates length of stay; RHF, right heart failure.
*Missing right heart failure status on 6 patients.
†
Rates were calculated by removing transplanted patients from the denominator.

those with moderate to severe vasoplegia having a median
serum creatinine of 1.6 mg/dL compared with 1.3 mg/dL
among those without vasoplegia. Also found to be predictive

of vasoplegia severity in this study were CVP and SBP, which
may be modiﬁed during the days of hospitalization before
surgery. Relatedly, those who develop vasoplegia are less

Figure 2. Cumulative incidence functions by severity of vasoplegia, adjusted by age and INTERMACS
(Interagency Registry for Mechanically Assisted Circulatory Support) proﬁle.

DOI: 10.1161/JAHA.117.008377
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Model

Vasoplegia Category

Estimate

95% CI

P Value

Model 1

Mild vs none

1.38

0.74–2.58

0.32

Moderate/severe vs none

1.99

1.08–3.69

0.03

Mild vs none

1.28

0.67–2.45

0.45

Moderate/severe vs none

2.12

1.08–4.18

0.03

Model 2

Model 1: unadjusted. Model 2: adjusted for age and INTERMACS (Interagency Registry
for Mechanically Assisted Circulatory Support) proﬁle. CI indicates conﬁdence interval.

likely to have baseline hypertenstion.7,11 Alternatively,
another study failed to detect a difference in baseline CVP;
however, it utilized patients with congenital heart defects and
only 10 patients had vasoplegia, which raises concerns about
statistical power and the appropriateness of generalization to
the advanced HF population of interest.14
Although ours is the ﬁrst model, to our knowledge, to
predict vasoplegia severity, existing models are often used to
allow surgeons to risk-stratify patients before surgery.
Although the MELD score was originally developed as a
prognostic score for patients with end-stage liver disease, it
has proven helpful for risk prediction of mortality and RHF
in patients undergoing heart transplantation and LVAD
implantation.15–17 The HeartMate II risk score involves a
combination of preoperative factors including age, albumin,
serum creatinine, international normalized ratio, and center
volume and is predictive of 90-day mortality following LVAD
implantation.18 That tool recently yielded controversial results
of varying mortality rates across INTERMACS proﬁles, which
suggested that the HeartMate II risk score may be superior to
traditional INTERMACS proﬁling for risk stratiﬁcation and that
INTERMACS proﬁles alone should not disqualify a candidate
from surgery.19 Our work demonstrated that the INTERMACS
proﬁle was more predictive of vasoplegia than the HeartMate
II risk score.
The development of a reliable prediction tool is critical
because vasoplegia has repeatedly been associated with poor
surgical outcomes. Patients who developed vasoplegia following elective cardiac surgery, for example, had signiﬁcantly
worse 90-day survival outcomes than those who did not
develop vasoplegia (29% versus 9%).7 Another study reported
a mortality rate of 50% for dialysis-dependent patients who
underwent CPB and subsequently developed vasoplegia.9 Our
work reiterated the association between vasoplegia and
mortality, as patients with moderate to severe vasoplegia
had a >2-fold increase in risk of mortality. In addition, we
observed higher rates of major bleeding episodes among
vasoplegic patients. This conﬁrms the work of Chan and
colleagues, who found a similar trend among transplant
recipients, and Patarroyo with blood transfusions.20,21
DOI: 10.1161/JAHA.117.008377

Although this ﬁnding may identify an area of confounding,
the majority of bleeding events after LVAD implantation
resolve within 24 hours. In our experience, 73% of the
bleeding events resolved within 24 hours. Furthermore,
patients developed respiratory failure at higher rates as
vasoplegia severity worsened, and we found that those with
moderate to severe vasoplegia developed RHF at 4 times
the rate of those who did not have vasoplegia. As a result of
these complications, the postoperative LOS for vasoplegic
patients was signiﬁcantly longer than for those without
vasoplegia, a theme that has been reported previously.22
Contrary to all other surgical outcomes, vasoplegia was
inversely related to driveline infection. This may be coincidental, or those with vasoplegia may have received prolonged
antibiotics due to concerns about sepsis, which could have
subsequently lowered the risk of driveline infection
development.
Attempts have been made to prevent and mitigate the
vasoplegia syndrome. In the United Kingdom, a liver transplantation department found that perfusing the liver at lower
oxygen tensions yielded a lower occurrence of vasoplegia.23
One center advocated for implanting LVADs via minimally
invasive procedures (ie, ministernotomy) to prevent
vasoplegia.24 Similarly, our work indicates that reducing the
time of CPB decreases the risk of developing vasoplegia. For
patients who have already developed vasoplegia, a randomized clinical trial revealed that those who went on to receive
vasopressin instead of norepinephrine had fewer postoperative complications.25 Furthermore, a literature review regarding the use of methylene blue (MB) as a treatment for
vasoplegia conﬁrmed that MB is safe if used within the
recommended dosage and is useful for treating vasoplegia,
although its beneﬁt is time-dependent.26 A newer study
reiterated this ﬁnding; CPB patients who received MB in the
operating room (early administration) had a mortality rate of
10.8% compared with 28.6% among those who received MB in
the intensive care unit (late administration).27 Controversy
exists regarding the use of MB in patients with both vasoplegia
and right ventricular failure; however, it is generally accepted
that its beneﬁts outweigh the risks. Because Mehaffey and
colleagues’ study was retrospective and observational, a
signiﬁcant knowledge gap remains regarding the potential
usefulness of MB therapy; therefore, a prospective randomized
trial may be warranted. We have not conducted formal
research studies regarding MB; however, we have observed
quick positive responses sustained for only a few hours.

Limitations
This study has all the limitations of a small, retrospective
review. These results were observed in a single center and
may not be generalizable to other centers. At our center, for
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Vasoplegia after heart transplantation: outcomes at 1 year. Interact Cardiovasc Thorac Surg. 2017;25:212–217.
4. Esmailian F, Perry P, Luu M, Patel J, Kittleson M, Czer L, Aintablian T, Zarrini P,
Velleca A, Rush J, Arabia F, Kobashigawa JA. Vasoplegia after heart
transplantation: unraveling the enigma. J Hear Lung Transplant. 2016;35:
S166–S167.
5. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a
competing risk. J Am Stat Assoc. 1999;94:496–509.
6. Kortekaas KA, Lindeman JH, Versteegh MI, Stijnen T, Dion RA, Klautz RJ.
Preexisting heart failure is an underestimated risk factor in cardiac surgery.
Neth Heart J. 2012;20:202–207.
7. van Vessem ME, Palmen M, Couperus LE, Mertens B, Berendsen RR, Tops LF,
Verwey HF, de Jonge E, Klautz RJ, Schalij MJ, Beeres SL. Incidence and
predictors of vasoplegia after heart failure surgery. Eur J Cardiothorac Surg.
2017;51:532–538.
8. Duran Bruce M, Gomar Sancho C, Holguera JC, Muliterno Espa~
nol E. Factors
involved in the development of vasoplegia after cardiac surgery with
extracorporeal circulation. A prospective observational study. Rev Esp
Anestesiol Reanim. 2014;61:246–253.
9. Hossne Junior NA, Miranda M, Monteiro MR, Branco JN, Vargas GF, Pestana JO,
Gomes WJ. Cardiopulmonary bypass increases the risk of vasoplegic syndrome
after coronary artery bypass grafting in patients with dialysis-dependent
chronic renal failure. Rev Bras Cir Cardiovasc. 2015;30:482–488.
10. Nearman H, Klick JC, Eisenberg P, Pesa N. Perioperative complications of
cardiac surgery and postoperative care. Crit Care Clin. 2014;30:527–555.
11. Mekontso-Dessap A, Hou€el R, Soustelle C, Kirsch M, Thebert D, Loisance DY.
Risk factors for post-cardiopulmonary bypass vasoplegia in patients with
preserved left ventricular function. Ann Thorac Surg. 2001;71:1428–1432.
12. Liu H, Yu L, Yang L, Green MS. Vasoplegic syndrome: an update on
perioperative considerations. J Clin Anesth. 2017;40:63–71.
13. Fida N, Loebe M, Estep JD, Guha A. Predictors and management of right heart
failure after left ventricular assist device implantation. Methodist Denbakey
Cardiovasc J. 2015;11:18–23.

Conclusions
Our study of 252 LVAD recipients reafﬁrmed that the
development of vasoplegia is a substantial risk following
surgery and a predictor of unfavorable surgical outcomes,
including death. Preoperative INTERMACS proﬁle, CVP, SBP,
and intraoperative CPB duration are all risk factors that may
be assessed before and during LVAD implantation. Work is
needed to determine whether modiﬁcation of these risk
factors, if possible, may limit the development and severity of
vasoplegia following LVAD implantation surgery.
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